Management of infection in systemic lupus erythematosus.

Abstract

Systemic lupus erythematosus (SLE) is a systemic autoimmune disease characterised by abnormal autoantibody production and clearance. This immunological background has been suggested to play a role in the susceptibility of SLE patients to infection. Moreover, drugs (most of them immunosuppressive or immunomodulating agents) used in the treatment of moderate and severe lupus give rise to a tendency for infections, including opportunistic ones. Infections may mimic the exacerbations of SLE, leading to confusion over the diagnosis and appropriate treatment. Despite increased awareness of this problem, infections remain a major source of morbidity and mortality in SLE. There are various strategies which can be applied to try and reduce the risk of infection in SLE patients. Options include vaccinations, antibiotic/antiviral prophylaxis and intravenous immunoglobulins.

• Authors: Savino Sciascia, Maria Jose Cuadrado, Mohammed Yousuf Karim
• Journal: Best practice & research. Clinical rheumatology (Best Pract Res Clin Rheumatol) Vol. 27 Issue 3 Pg. 377-89 (Jun 2013) ISSN: 1532-1770 [Electronic] Netherlands
• PMID: 24238694 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2013 Elsevier Ltd. All rights reserved.

Chemical References

• Autoantibodies
• Immunosuppressive Agents
• Vaccines

Topics

• Autoantibodies (blood)
• Bacterial Infections (drug therapy, immunology, microbiology)
• Humans
• Immunosuppressive Agents (therapeutic use)
• Lupus Erythematosus, Systemic (drug therapy, immunology, microbiology)
• Opportunistic Infections (drug therapy, immunology, microbiology)
• Risk Factors
• Vaccination
• Vaccines (administration & dosage)
• Virus Diseases (drug therapy, immunology, microbiology)